Медико-биологический
информационный портал
для специалистов
 
БИОМЕДИЦИНСКИЙ ЖУРНАЛ Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г.  2020 г.  2021 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Федеральное государственное бюджетное учреждение науки
"Институт токсикологии Федерального медико-биологического агентства"
(ФГБУН ИТ ФМБА России)

Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 18, Art. 39 (pp. 572-590)    |    2017       
»

Clinical and morphological study of prognostic factors NeuroD1, HLA-DR and Ki-67 in various types of adenomas of adrenal and pituitary glands
Galkovsky B.E., Vorobjeva O.M., Mitrofanova L.B.

Federal State Budgetary Institution Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation, Saint-Petersburg



Brief summary

Resume: One of the main tasks in the morphological study of adrenal and pituitary glands is the determination of the biological potential of tumors and, accordingly, the prognosis of the course of the disease. Objective: to study the role of NeuroD1, HLA-DR and Ki-67 in various types of adrenal and pituitary gland. Materials and methods: the medical history and surgical material from patients with 16 adrenal adenomas, 40 adenomas of the pituitary gland, autopsy material of 1 normal adrenal gland, and 9 pituitary glands were examined. The immunohistochemical study was performed with antibodies to Ki-67 and NeuroD1 in all cases, and to HLA-DR in all adrenal adenomas. Results of the study: expression of NeuroD1 was detected in all cases by adenomas, in the normal adrenal and pituitary. For adrenal glands, an inversely proportional significant relationship was found between the percentage of cells expressing NeuroD1 and the sum of the scores of the prognostic scales (r = -0.577 at p = 0.05). The expression level of NeuroD1 in the normal pituitary was significantly lower than in all 40 adenomas (p = 0.006). There were no significant differences between the level of Ki-67 expression between adrenal adenomas and the normal adrenal gland, as well as between various pituitary adenomas and the normal pituitary. There was no correlation between the level of Ki-67 proliferative activity, the HLA-DR expression area, the total scores on adrenal adenoma prognostic scales, and between the expression level of NeuroD1, hormones and Ki-67 in the pituitary. Conclusion: an immunohistochemical study showed that for the prognosis of adrenal adenoma and pituitary adrenal flow the most appropriate marker is NeuroD1, while Ki-67 has a low predictive value.


Key words

pituitary adenomas, adrenal adenomas, immunohistochemical study, NeuroD1, HLA-DR, Ki-67.





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1) Arnold DT, Reed JB, Burt K. Evaluation and management of the incidental adrenal mass. Proceedings (Baylor University Medical Center). 2003;16(1):7-12.


2) Mantero F., Masini A.M., Opocher G. et al. Adrenal Incidentaloma: An Overview of Clinical and Epidemiological Data from the National Italian Study Group. Horm Res 1997;47:284?289.


3) van der Zwan J. M., Mallone S., van Dijk B. et al. Carcinoma of endocrine organs: Results of the RARECARE project. European Journal of Cancer. 2012; 48(13):1923-1931.


4) Lau S.K., Weiss L.M. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Human Pathology. 2009; 40(6):757-768.


5) Dengqiang L., Yunze X., Lieyu X. Potential diagnostic and prognostic value of β-catenin and SF-1 in adrenocortical tumors. International journal of clinical and experimental pathology. 2017; 10(1): 401-408.


6) Kulkarni M. M., Khandeparkar G. S., Deshmukh S.D. - Risk Stratification in Paragangliomas with PASS (Pheochromocytoma of the Adrenal Gland Scaled Score) and Immunohistochemical Markers. Journal of clinical and diagnostic research. 2016; 10(9):EC1-EC4.


7) Ocal I., Avci A., Cakalagaoglu F. Lack of Correlations among Histopathological Parameters, Ki-67 Proliferation Index and Prognosis in Pheochromocytoma Patients. Asian Pacific Journal of Cancer Prevention. 2014; 15(4):1751-1755.


8) Agarwal A., Mehrotra P., Jain M. Size of the Tumor and Pheochromocytoma of the Adrenal Gland Scaled Score (PASS): Can They Predict Malignancy? World Journal of Surgery. 2010; 34(12): 3022-3028.


9) Wu D., Tischler A., Lloyd R. et al. Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score American journal of surgical pathology. 2009; 33(4): 599-608.


10) Marx C., Bornstein S. R., Wolkersdörfer G. W. et al. Relevance of Major Histocompatibility Complex Class II Expression as a Hallmark for the Cellular Differentiation in the Human Adrenal Cortex. Journal of Clinical Endocrinology & Metabolism. 1997; 82(9): 3136?3140.


11) Tani Y., Sugiyama T., Izumiyama H. et al. Differential gene expression profiles of POMC-related enzymes, transcription factors and receptors between non-pituitary and pituitary ACTH-secreting tumors. Endocr J. 2011; 58(4):297-303.


12) Pataskar A., Jung J., Smialowski P. et al. NeuroD1 reprograms chromatin and transcription factor landscapes to induce the neuronal program. EMBO J. 2016; 35(1): 24-45.


13) Oyama K, Sanno N., Teramoto A. et al. Expression of neuro D1 in human normal pituitaries and pituitary adenomas. Mod Pathol. 2001; 14(9): 892-9.


14) Bell G.I., Polonsky K.S. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2014; 14: 788?791. doi: 10.1038/414788a


15) Cerf M.E. Transcription factors regulating beta-cell function. Eur J Endocrinol 2006; 155: 671?679. doi: 10.1530/eje.1.02277


16) Lee J.E, Hollenberg S.M, Snider L., Turner D.L, Lipnick N., Weintraub H. Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein. Science 1995; 268: 836?844.


17) Malecki M.T, Jhala U.S, Antonellis A., Fields L., Doria A., Orban T. et al: Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet. 1999; 23:323?328.


18) Sharma A, Moore M, Marcora E, Lee J.E, Qiu Y., Samaras S. et al. The NeuroD1/BETA2 sequences essential for insulin gene transcription colocalize with those necessary for neurogenesis and p300/CREB binding protein binding. Mol Cell Biol. 1999; 19: 704?713.


19) Moates J.M, Nanda S., Cissell M.A, Tsai M.J, Stein R () BETA2 activates transcription from the upstream glucokinase gene promoter in islet beta-cells and gut endocrine cells. Diabetes 2003; 52: 403?408.


20) Mutoh H, Naya F.J, Tsai M.J, Leiter A.B. The basic helix-loop-helix protein BETA2 interacts with p300 to coordinate differentiation of secretin-expressing enteroendocrine cells. Genes Dev. 1998; 12: 820?830.


21) Konishi Y, Ohkawa N, Makino Y, Ohkubo H, Kageyama R, Furuichi T. et al. Transcriptional regulation of mouse type 1 inositol 1,4,5-trisphosphate receptor gene by NeuroD-related factor. J Neurochem. 1999; 72: 1717?1724.


22) Lloyd R.V., Osamura R.Y., Kloppel G., Rosai J. ((Eds): World Health Organization Classification of Tumors of Endocrine Organs, 4th Edition. IARC Press: Lyon; 2017. 355 p.


23) Suhardja A, Kovacs K, Rutka J. Role of transcription factors in the pathogenesis of pituitary adenomas: a review. J Neurooncol. 2001; 55: 185?193.


24) Asa S.L. Tumors of the pituitary gland. AFIP Atlas of Tumor Pathology. ARP Press: Washington; 2011. 283c.


25) Molatore S., Liyanarachchi S., Irmler M., Perren A. et al. ?Pheochromocytoma in Rats with Multiple Endocrine Neoplasia (MENX) Shares Gene Expression Patterns with Human Pheochromocytoma. Proc. of the National Academy of Sciences of the United States of America. 2010; 107(43): 18493?18498.


26) Marx C., Wolkersdörfer G.W., Brown J.W. et al. MHC class II expression--a new tool to assess dignity in adrenocortical tumours. The Journal of Clinical Endocrinology & Metabolism. 1996; 81(12): 4488?4491.


27) Mete O., Lopes M.B. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. Published online: 01 august 2017. https://doi.org/10.1007/s12022-017-9498-z


28) Al-Brahim N.Y.Y., Asa S.L. My approach to pathology of the pituitary gland. J Clin Pathol 2006;59:1245?1253.


29) Oyama K, Sanno N, Teramoto A et al. Expression of neuro D1 in human normal pituitaries and pituitary adenomas. Mod Pathol. 2001; 14(9): 892-9.


30) Umeoka K, Sanno N, Osamura RY et al. Expression of GATA-2 in human pituitary adenomas. Mod Pathol. 2002; 15(1): 11-17.


31) Cooper O, Ben-Shlomo A, Bonert V. et al. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer. 2010; 1(2): 80-92.


32) Ferretti E, Di Stefano D, Zazzeroni F, Gallo R. et al. Human pituitary tumours express the bHLH transcription factors NeuroD1 and ASH1. J. of Endocrinological Investigation. 2003; 26(10): 957?965.


33) Mutoh H, Naya F.J, Tsai M.J, Leiter A.B. The basic helix-loop-helix protein BETA2 interacts with p300 to coordinate differentiation of secretin-expressing enteroendocrine cells. Genes Dev. 1998; 12: 820?830.


34) Konishi Y, Ohkawa N, Makino Y, Ohkubo H et al. Transcriptional regulation of mouse type 1 inositol 1,4,5-trisphosphate receptor gene by NeuroD-related factor. J Neurochem. 1999; 72:1717?1724.


35) Liu M, Pereira F.A, Price S.D, Chu M.J et al. Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems. Genes Dev. 2000;14: 2839?2854.



Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100